Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P R Flatt

Showing results (271-280 of 281) with videos related to

Pageof 29
Sort By:
Journal of Molecular Endocrinology|December 11, 2003
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivoB D Green, V A Gault, M H Mooney, et al.
Metabolism: Clinical and Experimental|February 10, 2004
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.
The Journal of Endocrinology|March 12, 2004
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activityB D Green, M H Mooney, V A Gault, et al.
Biochemical Society Transactions|May 1, 1994
Effect of glucose and amino acids on insulin-secretion from a novel pancreatic B-cell line produced by electrofusionN H McClenaghan, T W Yoon, C R Barnett, et al.
The Journal of Endocrinology|October 27, 2006
Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob miceJ C Parker, K S Lavery, N Irwin, et al.
Peptides|January 11, 2020
CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell functionA G McCloskey, M G Miskelly, C B T Moore, et al.
Diabetes|August 1, 1996
Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusionN H McClenaghan, C R Barnett, E Ah-Sing, et al.
Peptides|November 9, 2000
Structure, antihyperglycemic activity and cellular actions of a novel diglycated human insulinF P O'Harte, A C Boyd, A M McKillop, et al.
Diabetes|December 2, 1999
ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 beta-cell lineJ C Chapman, N H McClenaghan, K E Cosgrove, et al.
Science (New York, N.Y.)|February 9, 1996
PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cellsL Eliasson, E Renström, C Ammälä, et al.
Pageof 29

Showing results (271-280 of 281) with videos related to

Sort By:
Pageof 29
Journal of Molecular Endocrinology|December 11, 2003
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivoB D Green, V A Gault, M H Mooney, et al.
Metabolism: Clinical and Experimental|February 10, 2004
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.
The Journal of Endocrinology|March 12, 2004
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activityB D Green, M H Mooney, V A Gault, et al.
Biochemical Society Transactions|May 1, 1994
Effect of glucose and amino acids on insulin-secretion from a novel pancreatic B-cell line produced by electrofusionN H McClenaghan, T W Yoon, C R Barnett, et al.
The Journal of Endocrinology|October 27, 2006
Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob miceJ C Parker, K S Lavery, N Irwin, et al.
Peptides|January 11, 2020
CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell functionA G McCloskey, M G Miskelly, C B T Moore, et al.
Diabetes|August 1, 1996
Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusionN H McClenaghan, C R Barnett, E Ah-Sing, et al.
Peptides|November 9, 2000
Structure, antihyperglycemic activity and cellular actions of a novel diglycated human insulinF P O'Harte, A C Boyd, A M McKillop, et al.
Diabetes|December 2, 1999
ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 beta-cell lineJ C Chapman, N H McClenaghan, K E Cosgrove, et al.
Science (New York, N.Y.)|February 9, 1996
PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cellsL Eliasson, E Renström, C Ammälä, et al.
Pageof 29